Skip to main content
. 2021 Nov 26;115(3):391–398. doi: 10.1007/s12185-021-03263-y

Table 3.

Summary of TEAEs (safety analysis set)

MedDRA preferred term Patients with malignant lymphoma (N = 51)
All grades Grade 3 or 4
Any TEAE 51 (100.0) 51 (100.0)
TEAEs occurring in ≥ 10% of patients
 Febrile neutropenia 49 (96.1) 49 (96.1)
 Diarrhea 42 (82.4) 6 (11.8)
 Stomatitis 32 (62.7) 13 (25.5)
 Nausea 29 (56.9)) 4 (7.8)
 Decreased appetite 28 (54.9) 16 (31.4)
 Malaise 24 (47.1) 0
 Dysgeusia 19 (37.3) 0
 Hepatic function abnormal 17 (33.3) 5 (9.8)
 Vomiting 15 (29.4) 1 (2.0)
 Hypokalemia 12 (23.5) 3 (5.9)
 Oropharyngeal pain 12 (23.5) 3 (5.9)
 Pharyngitis 12 (23.5) 3 (5.9)
 Pyrexia 11 (21.6) 0
 Hypersensitivity 10 (19.6) 1 (2.0)
 Dermatitis contact 9 (17.6) 0
 Insomnia 9 (17.6) 0
 Proctalgia 9 (17.6) 0
 Rash 7 (13.7) 0
 Headache 6 (11.8) 0

No grade 5 events were reported. Number of patients (%) are shown

MedDRA Medical Dictionary for Regulatory Activities, TEAE treatment-emergent adverse event